- 貨號: ajcp4380
- CAS: 52232-67-4
- 別名: Teriparatide Acetate; 醋酸特立帕肽; Human parathyroid hormone-(1-34); hPTH (1-34)
- 分子式: C181H291N55O51S2
- 分子量: 4117.75
- 純度: ＞98%
- 溶解度: ≥ 399.3mg/mL in DMSO, ≥ 19.88 mg/mL in Water
- 儲存: -20°C, away from moisture and light
- 庫存: 現貨
Background
Parathyroid hormone (1-34) (human) is the N-terminal fragment (34 amino acids) of human Parathyroid hormone (PTH) and is an agonist of the Parathyroid hormone 1 (PTH1) receptor[1]. PTH is essential for the regulation of extracellular Ca2+ and phosphate metabolism[2]. Parathyroid hormone (1-34) (human) can be used to treat osteoporosis. Injection of Parathyroid hormone (1-34) (human) can increase bone formation and bone mass without causing hypercalcemia[3, 4].
In vitro, Parathyroid hormone (1-34) (human) (0, 1, 10, 100nM) treatment of primary human osteoblasts for 24h induced an increase in angiopoietin 1 (Ang-1) mRNA expression. The 10nM dose increased the expression of Ang-1 mRNA by 2-fold (207%±6.4), but increasing the dose to 100nM did not further increase the expression level of Ang-1 mRNA[5].
In vivo, subcutaneous administration of Parathyroid hormone (1-34) (human) (20μg/kg/day) to mature rabbits for 4 weeks increased the cortical bone porosity, number and density, as well as the cortical area, thickness and bone mineral content (BMC) of the distal femoral shaft, but had no significant effect on volumetric bone mineral density (BMD)[6].
參考文獻:
[1]?Hoare S R J, Usdin T B. Molecular mechanisms of ligand recognition by parathyroid hormone 1 (PTH1) and PTH2 receptors[J]. Current pharmaceutical design, 2001, 7(8): 689-713.
[2]?Goltzman D. Physiology of parathyroid hormone[J]. Endocrinology and Metabolism Clinics, 2018, 47(4): 743-758.
[3]?Kim E S, Keating G M. Recombinant human parathyroid hormone (1–84): a review in hypoparathyroidism[J]. Drugs, 2015, 75: 1293-1303.
[4]?Neer R M, Arnaud C D, Zanchetta J R, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J]. New England journal of medicine, 2001, 344(19): 1434-1441.
[5]?Park J H, Song H I, Rho J M, et al. Parathyroid hormone (1-34) augments angiopoietin-1 expression in human osteoblast-like cells[J]. Experimental and clinical endocrinology & diabetes, 2006, 114(08): 438-443.
[6] Iwamoto J, Seki A, Nango N. Influence of teriparatide and ibandronate on cortical bone in New Zealand white rabbits: A HR-QCT study[J]. Calcified tissue international, 2016, 99(5): 535-542.
Parathyroid hormone (1-34) (human)是人類甲狀旁腺激素（PTH）的N端片段（34個氨基酸），是甲狀旁腺激素1（PTH1）受體的激動劑[1]。PTH對于細胞外Ca2+和磷酸鹽代謝的調節至關重要[2]。Parathyroid hormone (1-34) (human)可用于治療骨質疏松癥，注射Parathyroid hormone (1-34) (human)可以增加骨形成和骨量，而不會引起高鈣血癥[3, 4]。
在體外，Parathyroid hormone (1-34) (human)（0, 1, 10, 100nM）處理原代人類成骨細胞24h，誘導了血管生成素1（Ang-1）mRNA表達增加。10nM劑量下使Ang-1 mRNA的表達增加了2倍（207%±6.4），但劑量提高至100nM不會進一步增加Ang-1 mRNA表達水平[5]。
在體內，Parathyroid hormone (1-34) (human)（20μg/kg/day）通過皮下注射治療成熟家兔4周，增加了股骨遠端骨干的皮質骨孔隙比、數量和密度以及皮質面積、厚度和骨礦物質含量（BMC），但對體積骨礦物質密度（BMD）沒有顯著影響[6]。
Protocol
| Cell experiment [1]: | |
|
Cell lines |
Primary cultured human osteoblasts |
|
Preparation Method |
Primary cultured human osteoblasts were cultured in the presence of 0, 1, 10, and 100nM Parathyroid hormone (1-34) (human) for 24h. The expression of Ang-1 mRNA was analyzed by RT-PCR. |
|
Reaction Conditions |
0, 1, 10, 100nM; 24h |
|
Applications |
Parathyroid hormone (1-34) (human) induced an increase in Ang-1 mRNA expression. The Ang-1 mRNA levels, at 10nM Parathyroid hormone (1-34) (human), were 2-fold (207%±6.4) the levels of the control. Further increases in the concentration of Parathyroid hormone (1-34) (human) (to 100nM) did not further increase the levels of Ang-1 mRNA expression. |
| Animal experiment [2]: | |
|
Animal models |
Female New Zealand white rabbits |
|
Preparation Method |
Rabbits were randomized into six groups of 7 animals each as follows: 4-week vehicle administration group, 4-week Parathyroid hormone (1-34) (human) (TPTD) administration group (20μg/kg/day, s.c.), 12-week vehicle administration group, 4-week TPTD administration+8-week vehicle administration group, 4-week TPTD administration+8-week lower-dose ibandronate (IBN) administration group (20μg/kg, s.c., every 4 weeks), and 4-week TPTD administration+8-week higher-dose IBN administration group (100μg/kg, s.c., every 4 weeks). After the 4- or 12-week experimental period, the cortical bone of the distal femoral diaphysis was processed for HR-QCT analysis.? |
|
Dosage form |
20μg/kg/day, for 4 weeks; s.c. |
|
Applications |
Parathyroid hormone (1-34) (human) administration increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). |
|
參考文獻: |
|
